Drug Combination Details
| General Information of the Combination (ID: C67516) | |||||
|---|---|---|---|---|---|
| Name | Hesperidin NP Info | + | Diethylcarbamazine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatic fibrosis/cirrhosis
[ICD-11: DB93]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | GGT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TGFB1 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Adult male wistar rats (250-275 g) were used in this study. | |||||
| Experimental
Result(s) |
DEC when combined with HDN blunted EtOH-induced necroinflammation and elevation of liver injury parameters in serum. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. Biomed Pharmacother. 2017 May;89:1196-1206. | |||
